Neogen Chemicals Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Neogen Chemicals ont diminué à un taux annuel moyen de -5.7%, tandis que le secteur Chemicals a vu ses bénéfices augmenter de en à 6.2% par an. Les revenus ont augmenté de en à un taux moyen de 15.4% par an. Le rendement des capitaux propres de Neogen Chemicals est 3.5% et ses marges nettes sont de 3.3%.
Informations clés
-5.67%
Taux de croissance des bénéfices
-7.92%
Taux de croissance du BPA
| Chemicals Croissance de l'industrie | 17.68% |
| Taux de croissance des recettes | 15.45% |
| Rendement des fonds propres | 3.52% |
| Marge nette | 3.34% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Article d’analyse • May 24
Neogen Chemicals' (NSE:NEOGEN) Problems Go Beyond Weak Profit
The market wasn't impressed with the soft earnings from Neogen Chemicals Limited ( NSE:NEOGEN ) recently. We did some...Article d’analyse • Nov 16
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) earnings announcement last week contained some soft numbers, disappointing...Recent updates
Mise à jour du récit • Jun 16
NEOGEN: Preferential Share Issue Will Keep Future P E Excessively Elevated
Analysts have kept their fair value estimate for Neogen Chemicals steady at ₹1,455, citing relatively unchanged assumptions around revenue growth, profit margins and future P/E multiples, along with a slightly lower discount rate that fine tunes but does not materially shift their overall price target view. What’s in the News for Neogen Chemicals A board meeting is scheduled on May 16, 2026 to consider audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend recommendation for approval at the 37th AGM.Mise à jour du récit • Jun 02
NEOGEN: Preferential Equity Issue Will Sustain Pressure On Elevated Future P E
Analysts have raised their price target on Neogen Chemicals from ₹1,335 to ₹1,455, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for May 16, 2026 to consider audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider recommending a final dividend on equity shares, subject to shareholder approval at the 37th AGM.Article d’analyse • May 24
Neogen Chemicals' (NSE:NEOGEN) Problems Go Beyond Weak Profit
The market wasn't impressed with the soft earnings from Neogen Chemicals Limited ( NSE:NEOGEN ) recently. We did some...
Mise à jour du récit • May 11
NEOGEN: Preferential Equity Funding Will Support Long Term Upside Potential
Analysts have trimmed their price target for Neogen Chemicals from ₹2,630 to about ₹2,311 as they factor in more moderate revenue growth assumptions, a slightly higher profit margin outlook, and a lower future P/E multiple in their models. What's in the News Board meeting scheduled for April 18, 2026, to consider allotment of 1,000,000 equity shares with face value of ₹10 at an issue price of ₹1,610 per share on a preferential basis, aggregating up to ₹1,610,000,000.Mise à jour du récit • Apr 23
NEOGEN: Equity Fundraising Plans Will Pressure Elevated Future P E Multiple
Analysts have kept their price target for Neogen Chemicals steady at ₹1,335, citing only small refinements to their discount rate, revenue growth outlook and profit margin assumptions, along with a slightly lower future P/E multiple, rather than any major shift in the investment case. What's in the News On February 11, 2026, the board met to review unaudited standalone and consolidated results for the quarter and nine months ended December 31, 2025, and to evaluate various options for raising funds through equity and other securities in one or more tranches (company filing).Mise à jour du récit • Apr 09
NEOGEN: Future PE Reset Will Test Sustainability Of Recent Cost Improvements
Narrative Update Analysts have held the fair value estimate for Neogen Chemicals steady at ₹1,335.00 while updating assumptions on growth, margins and future P/E. This reflects recent research that cites stronger revenue and EBITDA performance, cost actions taking hold and higher external price targets in the range of roughly ₹540 to ₹1,000 equivalent.
Mise à jour du récit • Mar 25
NEOGEN: Raised Guidance And Cost Actions Will Support Higher Future Earnings Quality
Narrative Update Overview The revised analyst price target for Neogen Chemicals edges slightly lower to ₹1,756.25 from ₹1,769.57. This reflects updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while staying broadly aligned with recent Street research that has cited better revenue and EBITDA prints, higher guidance, and early benefits from cost actions.Mise à jour du récit • Mar 10
NEOGEN: Future P E Compression Will Challenge Optimism Around Cost Driven Margin Gains
Our updated fair value estimate for Neogen Chemicals shifts to ₹1,335 from ₹1,670 as analysts factor in slightly adjusted growth assumptions, a modestly lower discount rate, firmer profit margins and a reduced future P/E multiple, broadly in line with recent Street research that links higher targets in other names to improving revenue quality, cost actions and guidance. Analyst Commentary Street research around Neogen Chemicals points to a more measured setup, even as some peers in the sector see higher optimism baked into targets.Mise à jour du récit • Feb 24
NEOGEN: Raised Guidance And Cost Actions Will Support Richer Future Earnings Multiple
Analysts have trimmed their fair value estimate for Neogen Chemicals from ₹1,847 to about ₹1,770, as slightly softer revenue growth and margin inputs are being offset by a higher assumed future P/E multiple and recent Street target hikes following better than expected earnings and guidance. Analyst Commentary Recent Street research around Neogen Chemicals reflects a mix of optimism about execution and some caution on how durable the current momentum might be for earnings and valuation.Mise à jour du récit • Feb 10
NEOGEN: Raised Guidance And Cost Actions Will Support Further Upside
Narrative Update: Neogen Chemicals Analysts have lifted their price target on Neogen Chemicals to a range of about $10 to $12, up from $6.50 to $8. This change is attributed to the company’s recent revenue and EBITDA beat, raised guidance, and early benefits from portfolio execution and cost actions.Mise à jour du récit • Jan 26
NEOGEN: Raised Guidance And Upcoming Board Results Will Support Upside
Narrative Update The analyst price target for Neogen Chemicals has been adjusted from approximately ₹1,812 to ₹1,847 as analysts factor in recent research that points to steady fair value assumptions, a slightly higher discount rate, unchanged growth and margin inputs, and a modestly higher future P/E multiple in light of recent earnings commentary and guidance updates on Neogen. Analyst Commentary Recent Street research on Neogen Chemicals highlights a mix of optimism around execution and guidance, paired with some restraint on how far the valuation should stretch after the latest earnings release.Mise à jour du récit • Jan 09
NEOGEN: Steady Fair Value And Upcoming Results Will Support Upside
Analysts have kept their fair value estimate for Neogen Chemicals steady at ₹1,812.29 per share, with only marginal adjustments to the discount rate, revenue growth, profit margin and future P/E inputs that are too small to materially change the target at this time. What's in the News Board meeting scheduled for November 8, 2025, at 14:30 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Mise à jour du récit • Dec 26
NEOGEN: Market Perform Initiation Will Support Upside From Resilient Margins
Analysts have modestly revised their price target on Neogen Chemicals upward to $10, reflecting slightly higher long term growth expectations and largely stable margin and valuation assumptions. Analyst Commentary The latest initiation at a Market Perform rating with a $10 price target highlights a balanced view on Neogen Chemicals, with analysts seeing the current valuation as broadly aligned with its near to medium term growth prospects.Mise à jour du récit • Dec 11
NEOGEN: Market Perform Initiation Will Support Steady Future Return Potential
Analysts have nudged their price target for Neogen Chemicals slightly higher, reflecting a modest improvement in fair value to roughly ₹1,812 per share. This is supported by expectations of sustained high revenue growth and stable valuation multiples, despite only minor adjustments to discount rate and profit margin assumptions.Article d’analyse • Dec 04
Why We're Not Concerned Yet About Neogen Chemicals Limited's (NSE:NEOGEN) 26% Share Price Plunge
The Neogen Chemicals Limited ( NSE:NEOGEN ) share price has fared very poorly over the last month, falling by a...Mise à jour du récit • Nov 27
NEOGEN: Broader Customer Base And Joint Venture Will Support Steady Future Returns
Analysts have maintained Neogen Chemicals' price target at $1,806.57, citing stable growth expectations and aligning their assessment with the recent initiation of a Market Perform rating by the Street. Analyst Commentary Bullish Takeaways Bullish analysts note Neogen Chemicals' consistent revenue growth, which supports the current valuation and underpins the stable price target.Article d’analyse • Nov 16
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) earnings announcement last week contained some soft numbers, disappointing...Article d’analyse • Nov 14
Analysts Are More Bearish On Neogen Chemicals Limited (NSE:NEOGEN) Than They Used To Be
One thing we could say about the analysts on Neogen Chemicals Limited ( NSE:NEOGEN ) - they aren't optimistic, having...Mise à jour du récit • Nov 12
NEOGEN: Product Diversification Will Drive Long-Term Returns After New Joint Venture
Analysts have revised Neogen Chemicals' fair value target downward from ₹2,062.83 to ₹1,806.57. This adjustment is due to a slightly higher discount rate and moderated revenue growth expectations, as reflected in recent research updates.Article d’analyse • Nov 11
These 4 Measures Indicate That Neogen Chemicals (NSE:NEOGEN) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Mise à jour du récit • Aug 06
Expanding Lithium Battery Materials Will Secure Global Reach
Despite an upward revision in revenue growth forecasts, Neogen Chemicals’ consensus price target has been lowered to ₹2,062, primarily due to a substantial decline in its future P/E multiple. What's in the News Annual dividend decreased to INR 1 per share for FY 2024-25.
Nouveau récit • Mar 15
Merger With BuLi Chemicals Will Strengthen Market Position In Pharma And Agrochemicals
The merger and strategic product expansions aim to strengthen Neogen's market position and boost future export and domestic revenue growth.Article d’analyse • Feb 21
Neogen Chemicals Limited's (NSE:NEOGEN) P/S Is On The Mark
When you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...Article d’analyse • Feb 06
Neogen Chemicals Limited Just Missed Earnings - But Analysts Have Updated Their Models
It's been a pretty great week for Neogen Chemicals Limited ( NSE:NEOGEN ) shareholders, with its shares surging 16% to...Article d’analyse • Dec 26
Here's Why Neogen Chemicals (NSE:NEOGEN) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Dec 10
The Returns On Capital At Neogen Chemicals (NSE:NEOGEN) Don't Inspire Confidence
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Article d’analyse • Nov 20
Why Neogen Chemicals' (NSE:NEOGEN) Shaky Earnings Are Just The Beginning Of Its Problems
A lackluster earnings announcement from Neogen Chemicals Limited ( NSE:NEOGEN ) last week didn't sink the stock price...Article d’analyse • Nov 16
Earnings Miss: Neogen Chemicals Limited Missed EPS By 6.7% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Neogen Chemicals Limited ( NSE:NEOGEN ) released its second-quarter result to the...Article d’analyse • Sep 20
Investors Appear Satisfied With Neogen Chemicals Limited's (NSE:NEOGEN) Prospects As Shares Rocket 36%
The Neogen Chemicals Limited ( NSE:NEOGEN ) share price has done very well over the last month, posting an excellent...Article d’analyse • May 08
We Think That There Are More Issues For Neogen Chemicals (NSE:NEOGEN) Than Just Sluggish Earnings
Neogen Chemicals Limited's ( NSE:NEOGEN ) recent weak earnings report didn't cause a big stock movement. We think that...Article d’analyse • May 05
Earnings Miss: Neogen Chemicals Limited Missed EPS By 24% And Analysts Are Revising Their Forecasts
As you might know, Neogen Chemicals Limited ( NSE:NEOGEN ) last week released its latest full-year, and things did not...Article d’analyse • Apr 26
After Leaping 27% Neogen Chemicals Limited (NSE:NEOGEN) Shares Are Not Flying Under The Radar
Neogen Chemicals Limited ( NSE:NEOGEN ) shares have had a really impressive month, gaining 27% after a shaky period...Article d’analyse • Apr 12
Are Neogen Chemicals Limited (NSE:NEOGEN) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Neogen Chemicals fair value estimate is ₹1,238 Current share...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Neogen Chemicals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 8,620 | 288 | 901 | 0 |
| 31 Dec 25 | 8,182 | 197 | 919 | 0 |
| 30 Sep 25 | 7,996 | 261 | 816 | 0 |
| 30 Jun 25 | 7,843 | 336 | 684 | 0 |
| 31 Mar 25 | 7,776 | 348 | 686 | 0 |
| 31 Dec 24 | 7,744 | 494 | 653 | 0 |
| 30 Sep 24 | 7,374 | 404 | 663 | 0 |
| 30 Jun 24 | 7,057 | 374 | 651 | 0 |
| 31 Mar 24 | 6,907 | 357 | 660 | 0 |
| 31 Dec 23 | 6,949 | 330 | 662 | 0 |
| 30 Sep 23 | 7,168 | 467 | 617 | 0 |
| 30 Jun 23 | 7,032 | 486 | 499 | 0 |
| 31 Mar 23 | 6,862 | 500 | 500 | 0 |
| 31 Dec 22 | 6,391 | 513 | 448 | 0 |
| 30 Sep 22 | 5,855 | 471 | 410 | 0 |
| 30 Jun 22 | 5,505 | 484 | 353 | 0 |
| 31 Mar 22 | 4,873 | 446 | 334 | 0 |
| 31 Dec 21 | 4,231 | 383 | 281 | 0 |
| 30 Sep 21 | 3,757 | 364 | 250 | 0 |
| 30 Jun 21 | 3,445 | 326 | 215 | 0 |
| 31 Mar 21 | 3,364 | 313 | 209 | 0 |
| 31 Dec 20 | 3,260 | 293 | 221 | 0 |
| 30 Sep 20 | 3,231 | 290 | 216 | 0 |
| 30 Jun 20 | 3,183 | 293 | 180 | 0 |
| 31 Mar 20 | 3,061 | 287 | 200 | 0 |
| 31 Dec 19 | 3,036 | 301 | 195 | 0 |
| 30 Sep 19 | 2,846 | 262 | 180 | 0 |
| 30 Jun 19 | 2,555 | 225 | 152 | 0 |
| 31 Mar 19 | 2,391 | 209 | 142 | 0 |
| 31 Mar 18 | 1,612 | 110 | 108 | 0 |
| 31 Mar 17 | 1,101 | 77 | 71 | 0 |
| 31 Mar 16 | 1,003 | 52 | 59 | 0 |
Des revenus de qualité: NEOGEN a un niveau élevé de bénéfices non monétaires.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de NEOGEN sont inférieures à celles de l'année dernière NEOGEN. (3.3%) sont inférieures à celles de l'année dernière (4.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de NEOGEN ont diminué de 5.7% par an au cours des 5 dernières années.
Accélération de la croissance: NEOGEN a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: NEOGEN a enregistré une croissance négative de ses bénéfices ( -17.5% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Chemicals ( 13.6% ).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de NEOGEN ( 3.5% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/18 20:42 |
| Cours de l'action en fin de journée | 2026/06/18 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Neogen Chemicals Limited est couverte par 16 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| null null | Asian Markets Securities Private Limited |
| Vijayaraghavan Swaminathan | Avendus Spark |